KarXT (xanomeline-trospium) provides meaningful reductions in symptoms of schizophrenia at 52 weeks, Bristol Myers Squibb announced on April 6, 2024.
Xanomeline-trospium offers a new way to treat schizophrenia since. Opposed to regulating the dopamine receptor like most drugs approved for schizophrenia do, xanomeline-trospium indirectly modules the dopamine and neurotransmitters responsible for schizophrenia.
The drug was evaluated in the EMERGENT program, and the most recently announced data comes from the EMERGENT-4 trial, a phase 3 open-label extension trial evaluating the long-term efficacy, safety, and tolerability of xanomeline-trospium in adults with schizophrenia, particularly at 52 weeks.
In an interview with HCPLive, Rishi Kakar, MD, from Segal Trials, discussed the significance of this 52-week data and what are the next steps for research.
“Over 75% of the participants had at least a 30% improvement in the symptoms at the length of 52 weeks,” Kakar said. “So, I think that's a very promising data.”
Interview Highlights:
Significance of the data: 0:07
Challenges during the Emergent Program: 2:27
Next steps for research: 6:47
Check out the article here: www.hcplive.com/view/insight-...
Other schizophrenia content: www.hcplive.com/clinical/schi...
Other Psychiatry content: www.hcplive.com/clinical/psyc...
#EMERGENT #EMERGENT-4 #KarXT # Xanomeline-trospium #schizophrenia #long-term efficacy
25 апр 2024
